Latest Patient Enrolment News

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.

Opthea Limited reports steady progress in its Phase 3 trials for sozinibercept, a novel treatment for wet AMD, supported by a strong cash position and a recent R&D tax incentive.

Invion Limited has marked significant progress in its cancer treatment pipeline, dosing the first patient in a pivotal skin cancer trial and reporting encouraging prostate cancer results, while securing fresh funding to support ongoing development.

Mesoblast Limited is set to launch Ryoncil®, the first FDA-approved MSC therapy for pediatric steroid-refractory acute graft-versus-host disease, backed by a recent $160 million financing that strengthens its commercial and clinical development efforts.

Amplia Therapeutics has completed enrolment for its ACCENT Phase 2a trial in advanced pancreatic cancer two months early, reporting encouraging partial response rates and improved patient outcomes.

Imugene Limited reports durable patient responses in multiple cancer immunotherapy trials and strengthens its financial position with a $46 million convertible note deal and a substantial R&D tax refund.

Paradigm Biopharmaceuticals has secured FDA clearance for its phase 3 knee osteoarthritis trial and raised $16 million to fund its next clinical steps, positioning the company for a pivotal year ahead.

Argenica Therapeutics has received a positive safety review from its independent DSMB for the Phase 2 trial of ARG-007 in acute ischaemic stroke patients, with dosing now 86% complete and full recruitment expected by early Q2 2025.

Cynata Therapeutics reports encouraging Phase 1 results for its diabetic foot ulcer treatment CYP-006TK, alongside a strengthened balance sheet and ongoing clinical progress.

Respiri Limited reports a standout December quarter marked by a 67% surge in patient program enrolments and robust revenue growth, bolstered by strategic acquisition synergies from Orb Health. The company is poised for further expansion in 2025 amid promising contract negotiations and evolving US healthcare reimbursement policies.

Next Science reported a 2.9% revenue increase to US$22.8 million in FY24, driven by an 85% surge in XPERIENCE™ sales, while achieving adjusted EBITDA and cashflow positivity in 4Q FY24 amid strategic cost restructuring.

Anatara Lifesciences has successfully completed recruitment for the second stage of its pivotal GaRP-IBS clinical trial, with headline results expected in Q1 2025. The company also launched a new anti-obesity project and strengthened its cash position through recent capital raises.